ESMO 2018 Prostate Cancer
- 796PD - Detection of circulating tumor DNA in de novo metastatic castrate-sensitive prostate cancer – Werner Strauss et al.
- 797PD - LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival in patients with metastatic hormone-sensitive prostate cancer receiving ADT+abiraterone acetate and prednisone or placebo – Nobiaki Matsubara et al.
- 798PD - In-depth assessment of metastatic prostate cancer with the high tumor mutational burden – Niven Mehra et al.
- 799PD - Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC) – Scott Tagawa et al.
Munich, Germany (UroToday.com) Dr. Winald R. Gerritsen gave an overview of the role of immunotherapy in prostate cancer.
There have been several vaccinations that have been specifically developed for prostate cancer. These include:
- Sipuleucel T – demonstrating a median four months overall survival advantage vs. placebo, with an immune response in 70% of patients
- G-VAX – Two phase 3 studies comparing it vs. docetaxel had failed
Munich, Germany (UroToday.com) Enzalutamide is an androgen signaling inhibitor which prevents androgen receptor nuclear translocation and DNA binding, therefore leading to cellular apoptosis. Enzalutamide has been largely studied in the metastatic castration-resistant population, demonstrating an overall survival benefit for patients before and after chemotherapy1,2. In an open-label, single arm, phase II study, enzalutamide was also found to be well tolerated in patients with castration-sensitive prostate cancer, with 92.5% of patients achieving at 80% PSA decline or greater by week 25 of therapy3. However, it is unknown if enzalutamide is more effective than bicalutamide in combination with standard ADT for patients with metastatic castration sensitive prostate cancer.